Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00426478|
Recruitment Status : Completed
First Posted : January 24, 2007
Last Update Posted : August 22, 2008
A double-blind, active-controlled, randomized trial to compare Valsartan plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5 mg.
Study design: 2 weeks washout, 8 weeks treatment period.
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: Valsartan plus Hydrochlorothiazide (80mg/12.5mg) Drug: Amlodipine (5mg)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Comparison of the Antihypertensive Efficacy and Tolerability Between Valsartan Plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5mg in the Essential Hypertensive Patients|
|Study Start Date :||November 2006|
|Actual Study Completion Date :||September 2007|
- Change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks treatment
- Change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks treatment
- Change from baseline in Ambulatory Blood Pressure Measurement (ABPM) parameters after 8 weeks treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426478
|National Taiwan University|
|Taipei, R.o.c, Taiwan, 100|
|Principal Investigator:||Jeremiah CHAO, MD||National Taiwan Univ|